Pembrolizumab in microsatellite instability high (MSI-H)/ mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.

JOURNAL OF CLINICAL ONCOLOGY(2021)

引用 4|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要